GVHD
Optimizing Pharmacotherapy In Chronic GVHD
Chronic graft-versus-host disease can occur in a multitude of organs, often characterized by fibrosis or ...
JUNE 13, 2025
Long-Term Management of Solid-Organ and Hematopoietic Cell Transplant Recipients
The long-term success of solid-organ transplant recipients greatly hinges on effective maintenance ...
DECEMBER 18, 2024
Steroids Still the Mainstay Treatment for cGVHD
Corticosteroids remain an effective tool for treating chronic graft-versus-host disease, although they are ...
DECEMBER 15, 2024
FDA Approves Niktimvo for Chronic Graft-Versus-Host Disease
The FDA has approved Niktimvo for the treatment of chronic graft-versus-host disease after failure of at least two ...
AUGUST 15, 2024
Strides Made in the ‘Slow Game’ of Conquering cGVHD
Organ and tissue transplantation is known to save lives, but it brings disadvantages, too.
FEBRUARY 17, 2023
New Pediatric Indication for Ibrutinib Granted to Treat GVHD
The FDA granted a new indication for Imbruvica for children 12 months of age and older with cGVHD after failure of ...
AUGUST 25, 2022
New Approvals for GVHD Expand Treatment Options
For years, therapeutic options for graft-versus-host disease (GVHD) had been limited. Although several recent ...
AUGUST 17, 2022
Jakafi Approved To Treat Chronic GVHD in Adults and Children
The FDA approved ruxolitinib (Jakafi, Incyte) for chronic graft-versus-host disease after failure of one or two ...
OCTOBER 15, 2021
Oral JAK Inhibitor Shows Efficacy for Steroid-Refractory Graft-Versus-Host Disease
The oral JAK inhibitor ruxolitinib is associated with significant clinical improvement in patients with ...
JANUARY 29, 2021
FDA Approves Jakafi to Treat Acute GVHD
The FDA granted a new indication for Jakafi to treat steroid-refractory acute graft-versus-host disease in adults ...
MAY 28, 2019
Low-Dose IL-2, Abatacept Show Benefit in GVHD
Researchers are making progress in efforts to combat the dangerous, often deadly, graft-versus-host disease that ...
JANUARY 18, 2018
FDA Approves Imbruvica to Treat Adults With Chronic GVHD
Imbruvica becomes the first and only therapy specifically approved for adults with cGVHD, a serious and ...
AUGUST 7, 2017
